Phase 2 Kidney Cancer Trial, Recruiting NCT07227415 Sponsor: Pfizer Condition: Kidney Cancer
Back to Kidney Cancer

Phase 2 Kidney Cancer Trial, Recruiting

NCT07227415
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with kidney cancer (RCC) that has spread or cannot be removed or treated with radiation, confirmed by a tissue or cell sample
  • You have at least one tumour that can be measured by scans and has not yet been treated
  • Your blood, liver, heart, and kidney functions are at acceptable levels (as determined by the trial team)
  • You have not had previous drug or systemic treatment for your kidney cancer (some immunotherapy given after surgery may be allowed if it was more than 12 months ago)
  • Your general health and ability to carry out daily activities meets a certain level (known as ECOG 0 or 1 — meaning you are fully active or have minor restrictions) (confirm with trial site)
  • You fall into any risk category based on a standard kidney cancer risk scoring system called IMDC (confirm with trial site)

Who may not be able to join:

  • You have active cancer that has spread to the brain, spinal cord, or surrounding membranes
  • You have a significant risk of bleeding or developing abnormal connections between body tissues (fistula)
  • You have been diagnosed with another cancer within the past 3 years
  • You have had an organ transplant or bone marrow/stem cell transplant from another person
  • You have an active autoimmune disease that has required medication within the last 2 years
  • You have had uncontrolled heart problems or other serious health conditions within the past 6 months
  • You have had major surgery or serious injury within the past 4 weeks, or are planned to have major surgery during the study
  • You have a history of serious bleeding problems or issues with blood clotting
  • You have had certain serious digestive or stomach problems (such as severe ulcers, bowel blockage, internal abscess, or active bleeding) within the past 6 months
  • You currently have an active, ongoing, or symptomatic infection
  • You have a history of a weakened immune system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Australian sites

Icon Cancer Centre Wesley, Auchenflower, Queensland
Monash Health, Clayton, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
10 February 2026
Est. completion
2 November 2027

Where this trial is recruiting

🇦🇺 Australia 🇨🇳 China 🇩🇪 Germany 🇯🇵 Japan 🇪🇸 Spain 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator; Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs); Number of participants with dose limiting toxicity (DLT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov